Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Saifo, Maher S ^a,b   Rempinski Jr, Donald R ^a   Rustum, Youcef M ^a   Azrak, Rami G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b DAMASCUS UNIVERSITY   (Syrian Arab Republic)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BETA CATENIN; CHLORTETRACYCLINE; CYCLOHEXIMIDE; DOCETAXEL; FLUOROURACIL; GLYCOGEN SYNTHASE KINASE 3BETA; IRINOTECAN; LITHIUM CHLORIDE; METHYLSELENINIC ACID; ONCOPROTEIN; OXALIPLATIN; PACLITAXEL; SELENIUM; SHORT HAIRPIN RNA; TOPOTECAN; UNCLASSIFIED DRUG; METHYLSELENIC ACID; ORGANOSELENIUM DERIVATIVE; PLATINUM COMPLEX; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL TYPE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG TARGETING; ENZYME PHOSPHORYLATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; KNOCKOUT GENE; MALE; NONHUMAN; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTON TRANSPORT; SOLID TUMOR; TREATMENT OUTCOME; TUMOR XENOGRAFT; GENETICS; METABOLISM; NEOPLASM; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; ORGANOSELENIUM COMPOUNDS; PACLITAXEL; RNA INTERFERENCE; TAXOIDS; TOPOTECAN;

EID: 78649570880     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-310     Document Type: Article

References (41)

1. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653:1-24.
2. Yang F, Zeng Q, Yu G, Li S, Wang CY. Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal 2006, 18:679-687. 10.1016/j.cellsig.2005.06.015, 16084063.
3. Goto M, Mitra RS, Liu M, Lee J, Henson BS, Carey T, Bradford C, Prince M, Wang CY, Fearon ER, D'Silva NJ. Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res 2010, 16:65-76. 10.1158/1078-0432.CCR-09-1122, 20028760.
4. Tsai YP, Yang MH, Huang CH, Chang SY, Chen PM, Liu CJ, Teng SC, Wu KJ. Interaction between HSP60 and beta-catenin promotes metastasis. Carcinogenesis 2009, 30:1049-1057. 10.1093/carcin/bgp087, 19369584.
5. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih Ie M, Buhler K, Pienta K, Rubin MA, Vessella R, Papadopoulos N. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002, 34:9-16. 10.1002/gcc.10037, 11921277.
6. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000, 45:323-334. 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W, 11102958.
7. Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol 2007, 27:7551-7559. 10.1128/MCB.01034-07, 2169070, 17785439.
8. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790. 10.1126/science.275.5307.1787, 9065402.
9. Wagenaar RA, Crawford HC, Matrisian LM. Stabilized beta-catenin immortalizes colonic epithelial cells. Cancer Res 2001, 61:2097-2104.
10. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998, 58:1130-1134.
11. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 2002, 109:987-991. 150951, 11956233.
12. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, Wedlich D, Birchmeier W. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998, 280:596-599. 10.1126/science.280.5363.596, 9554852.
13. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998, 8:573-581. 10.1016/S0960-9822(98)70226-X, 9601641.
14. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. Embo J 1998, 17:1371-1384. 10.1093/emboj/17.5.1371, 1170485, 9482734.
15. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996, 10:1443-1454. 10.1101/gad.10.12.1443, 8666229.
16. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43:1158-1164. 10.1016/S0028-3908(02)00215-0, 12504922.
17. Beurel E, Kornprobst M, Blivet-Van Eggelpoel MJ, Ruiz-Ruiz C, Cadoret A, Capeau J, Desbois-Mouthon C. GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp Cell Res 2004, 300:354-364. 10.1016/j.yexcr.2004.08.001, 15475000.
18. Cliffe A, Hamada F, Bienz M. A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling. Curr Biol 2003, 13:960-966. 10.1016/S0960-9822(03)00370-1, 12781135.
19. Nusse R. Cell biology: relays at the membrane. Nature 2005, 438:747-749. 10.1038/438747a, 16340998.
20. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 1996, 59:3-10. 10.1016/0925-4773(96)00597-7, 8892228.
21. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, Destree O, Clevers H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996, 86:391-399. 10.1016/S0092-8674(00)80112-9, 8756721.
22. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999, 96:5522-5527. 10.1073/pnas.96.10.5522, 21892, 10318916.
23. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426. 10.1038/18884, 10201372.
24. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512. 10.1126/science.281.5382.1509, 9727977.
25. Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, Kim HS, Lee SH, Kim SY, Park YG, An WG, Jang JJ, Yoo NJ, Lee JY. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol 2001, 193:483-490. 10.1002/1096-9896(2000)9999:9999<::AID-PATH804>3.0.CO;2-R, 11276007.
26. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008, 452:650-653. 10.1038/nature06835, 18385740.
27. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850. 10.1038/nature03319, 15829953.
28. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001, 6:81-91. 10.1634/theoncologist.6-1-81, 11161231.
29. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
30. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245. 10.1200/JCO.2007.12.4008, 18182665.
31. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-1704. 10.1056/NEJMoa071028, 17960012.
32. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004, 10:2561-2569. 10.1158/1078-0432.CCR-03-0268, 15073137.
33. Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther 2006, 5:2540-2548. 10.1158/1535-7163.MCT-05-0546, 2826137, 17041098.
34. Combs GF, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998, 79:179-192. 10.1016/S0163-7258(98)00014-X, 9776375.
35. Goldhaber SB. Trace element risk assessment: essentiality vs. toxicity. Regul Toxicol Pharmacol 2003, 38:232-242. 10.1016/S0273-2300(02)00020-X, 14550763.
36. Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr 2004, 58:391-402. 10.1038/sj.ejcn.1601800, 14985676.
37. Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, Green R, Shen B, Liu JO. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol 2010, 6:209-217. 10.1038/nchembio.304, 2831214, 20118940.
38. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6:1664-1668. 10.1016/S0960-9822(02)70790-2, 8994831.
39. Zhang W, Yan S, Liu M, Zhang G, Yang S, He S, Bai J, Quan L, Zhu H, Dong Y, Xu N. β-catenin/TCF pathway plays a vital role in selenium induced-growth inhibition and apoptosis in esophageal squamous cell carcinoma (ESCC) cells. J canlet 2010, 296:113-122.
40. Chintala S, Toth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM. Se-methylselenocysteine sensitize hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol 2010, 66:899-911. 10.1007/s00280-009-1238-8, 20066420.
41. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP, Sarkar FH. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 2007, 282:21542-21550. 10.1074/jbc.M701978200, 17522055.